Navigation Links
cGMP Safe Deposit Facility from European Collection of Cell Cultures (ECACC)

ProductscGMP Safe Deposit Facility from European Collection of Cell Cultures (ECACC)
Company European Collection of Cell Cultures (ECACC)
Item cGMP Safe Deposit Facility
Price 
Description cGMP Safe Deposit Service

ECACC is able to accept cell lines produced according to the requirements of cGMP for cryo-storage. The cell lines must be accompanied by a certificate to confirm they have been produced in accordance with the requirements of cGMP and that they have been tested for freedom from mycoplasma, bacteria or fungi. What are the benefits of the cGMP Safe Deposit Service?

Second site storage:
The ECACC cGMP Safe Deposit Service enables customers to comply with the requirements of cGMP by providing secure second site storage. The service is not designed to be used as the sole or primary site of storage.
Monitoring: The cGMP dedicated storage tank is monitored continuously by a chart recorder linked to a telemetry alarm system. ECACC monitor cell lines stored in the same vessel are periodically resuscitated and cultured to further confirm that conditions favourable for preserving cell lines are maintained.

Storage Conditions:
Cell lines are stored in vapour phase above a liquid nitrogen reservoir. The ampoules are placed within an aluminium cryo-box that can hold up to 100 ampoules. The depositor can request to have separate cryo-boxes for each cell line deposited or multiple deposits in one cryo-box. Cryo-boxes are exclusive to each customer.
Facilities: The cGMP dedicated storage vessel is housed in a purpose built ultra low storage facility which is one of the largest liquid nitrogen repositories in Europe. The facility can accommodate 50 liquid nitrogen storage vessels each containing up to 25,000 ampoules.
Validation: The purpose built ultra low storage facility has been validated by Installation Qualification (IQ). The dedicated cGMP storage vessel has been subjected to a formal IQ/Operational Qualification (OQ)/Performance Qualification (PQ) validation exercise. The chart recorder has been tested to IQ/OQ.

Security:
The site benefits from the high level of security that applies to the Centre for Emergency Preparedness and Response, Health Protection Agency, Porton Down. Security staff are present on site 24 hours a day and access to the ultra low storage facility is restricted to authorised personnel only. All the inventory storage vessels are configured for automatic liquid nitrogen replenishment and each vessel is alarmed and monitored by an electronic telemetry system.

Info European Collection of Cell Cultures (ECACC) European Collection of Cell Cultures (ECACC)
United Kingdom
Customer Service: +44 (0) 1980 612684
Fax Number: +44 (0) 1980 611315
Web Site: http://www.ecacc.org.uk/
NOTE: Price information is approximate list price and actual prices may vary.

Related biology products :

1. Mouse Anti-Human Caspr2 Monoclonal Antibody, Unconjugated, Clone K67/25 from UC Davis/NINDS/NIMH NeuroMab Facility
2. Mouse Anti-Mouse BKBeta2 potassium channel Monoclonal Antibody, Unconjugated, Clone N53/32 from UC Davis/NINDS/NIMH NeuroMab Facility
3. The National Collection of Pathogenic Viruses (NCPV) from European Collection of Cell Cultures (ECACC)
4. CnC (Cn402-05) from European Collection of Cell Cultures (ECACC)
5. CAOSMC (C354-05) from European Collection of Cell Cultures (ECACC)
6. CnAOSMC (Cn354-05) from European Collection of Cell Cultures (ECACC)
7. PPAEC (P302-05) from European Collection of Cell Cultures (ECACC)
8. PPASMC (P352-05) from European Collection of Cell Cultures (ECACC)
9. HER2plus Control Slides from European Collection of Cell Cultures (ECACC)
10. BBMVEC (B840-05) from European Collection of Cell Cultures (ECACC)
11. BAOSMC (B354-05) from European Collection of Cell Cultures (ECACC)
... immunoaffinity purified antibody detects an ~185 kDa ... of ErbB-2 phosphorylated at tyrosine 1248 on ... been cross adsorbed against the non-phosphorylated peptide ... non-phosphorylated form of the protein. In ...
Mouse monoclonal [4A2.2] to SLC6A4 ( Abpromise for all tested applications). entrezGeneID: 6532 SwissProtID: P31645...
...
... The complete SSCP kit provides all ... mutation detection by single-stranded conformation polymorphism analysis ... system. The kit includes a cooling finger ... (not provided), 2 sets of 20 cm ...
Biology Products:
(Date:5/11/2015)... 11, 2015 Curemark LLC, a privately held ... a new Phase III double blind, randomized, placebo-controlled clinical ... CM-AT, on all children ages 3-8 with Autism. Previously, ... III double blinded clinical trial for CM-AT in children ... the digestive enzyme chymotrypsin. This new trial will help ...
(Date:5/8/2015)... Synaptics Inc. (NASDAQ: SYNA ), the leading ... the executive management team will present at the following investor ... Telecom Conference Date: May 18, 2015 Time: 10:40am ... Cowen and Company Technology, Media & ... The New York Palace Hotel, New York, NY ...
(Date:5/6/2015)... 2015 LifeBEAM, a developer of bio-sensing technology, ... today that they will expand their partnership in bio-sensing ... cycling helmet and the first joint project between the ... in order to give cyclists more style choices and ... and Lazer announced their plan to release a new ...
Breaking Biology News(10 mins):Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2Synaptics to Present at Upcoming Investor Conferences 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 3
... of the 1962 Nobel Prize with Francis Crick and Maurice ... DNA, will present "Curing Incurable Cancer" and attend other events ... the James Graham Brown Cancer Center at the University of ... 5, at the Brown Theater, 315 W. Broadway, Louisville. Admission ...
... early stages of a major cause of failure in joint ... avoid additional surgery. More than 1.5 million total joint replacement ... is 90 per cent, almost 10 per cent of implants ... journal Molecular Pharmaceutics . Dong Wang and colleagues ...
... do not rely on oxygen may have played an important ... to a theory that UChicago researcher Albert Colman is testing ... Siberia. He has found that bacteria at the site ... that scientists must take into account as they attempt to ...
Cached Biology News:UofL hosts address by Nobel Laureate, DNA structure co-discoverer James Watson 2Cold case: Siberian hot springs reveal ancient ecology 2Cold case: Siberian hot springs reveal ancient ecology 3
(Date:5/21/2015)... , May 21, 2015  CytRx Corporation (NASDAQ: ... company specializing in oncology, today announced positive updated ... with aldoxorubicin for the treatment of unresectable glioblastoma ...  The open-label, multisite trial is designed to investigate ... patients whose tumors have progressed following prior treatment ...
(Date:5/21/2015)... 21, 2015 /PRNewswire/ - RepliCel Life Sciences Inc. ... medicine company focused on the development of autologous ... at the International Society for Cellular Therapy (ISCT) ... tendinosis currently in a Phase 1/2 clinical trial.  ... from 5:30 PM to 7:00 PM local ...
(Date:5/20/2015)... , May 20, 2015 ... presented preliminary data demonstrating the ability of the ... fibrosis (IPF) from other interstitial lung diseases (ILDs) ... the classifier,s potential to help thousands of patients ... ambiguity in IPF diagnosis – a frequent challenge ...
(Date:5/20/2015)... , May 19, 2015 Research and Markets ... of the "Global Cell Therapy Market Outlook 2020 ... of cell therapy in tissue and regenerative medicine is ... no other options which could help in the growth ... this segment but they are unable to form new ...
Breaking Biology Technology:CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7RepliCel to Present Unique Autologous Cell Treatment for Achilles Tendinosis at International Society for Cellular Therapy Conference 2RepliCel to Present Unique Autologous Cell Treatment for Achilles Tendinosis at International Society for Cellular Therapy Conference 3Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 2Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 3Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 4Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 5Global Cell Therapy Market Outlook 2015-2020 - 262 Cell Therapies & 13 Marketed Cell Therapies 2Global Cell Therapy Market Outlook 2015-2020 - 262 Cell Therapies & 13 Marketed Cell Therapies 3